Waldron Private Wealth LLC Grows Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Waldron Private Wealth LLC boosted its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1.6% in the third quarter, HoldingsChannel reports. The fund owned 5,083 shares of the pharmaceutical company’s stock after purchasing an additional 78 shares during the quarter. Waldron Private Wealth LLC’s holdings in Vertex Pharmaceuticals were worth $2,364,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of VRTX. Eastern Bank purchased a new position in shares of Vertex Pharmaceuticals in the 3rd quarter valued at approximately $805,000. Signaturefd LLC raised its holdings in shares of Vertex Pharmaceuticals by 1.1% in the third quarter. Signaturefd LLC now owns 5,149 shares of the pharmaceutical company’s stock worth $2,395,000 after buying an additional 55 shares during the last quarter. Sequoia Financial Advisors LLC raised its holdings in shares of Vertex Pharmaceuticals by 10.3% in the third quarter. Sequoia Financial Advisors LLC now owns 12,288 shares of the pharmaceutical company’s stock worth $5,715,000 after buying an additional 1,147 shares during the last quarter. Oakworth Capital Inc. lifted its stake in shares of Vertex Pharmaceuticals by 17.6% during the third quarter. Oakworth Capital Inc. now owns 167 shares of the pharmaceutical company’s stock worth $78,000 after buying an additional 25 shares during the period. Finally, Foundations Investment Advisors LLC grew its holdings in shares of Vertex Pharmaceuticals by 11.3% during the third quarter. Foundations Investment Advisors LLC now owns 849 shares of the pharmaceutical company’s stock valued at $395,000 after buying an additional 86 shares during the last quarter. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, CMO Carmen Bozic sold 2,280 shares of the business’s stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $476.75, for a total transaction of $1,086,990.00. Following the transaction, the chief marketing officer now owns 23,259 shares of the company’s stock, valued at approximately $11,088,728.25. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Vertex Pharmaceuticals news, CMO Carmen Bozic sold 2,280 shares of Vertex Pharmaceuticals stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $476.75, for a total transaction of $1,086,990.00. Following the transaction, the chief marketing officer now directly owns 23,259 shares of the company’s stock, valued at $11,088,728.25. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Sangeeta N. Bhatia sold 646 shares of the stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $500.00, for a total transaction of $323,000.00. Following the completion of the sale, the director now directly owns 4,435 shares of the company’s stock, valued at approximately $2,217,500. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 14,285 shares of company stock worth $7,101,755 in the last ninety days. Insiders own 0.20% of the company’s stock.

Wall Street Analyst Weigh In

VRTX has been the subject of a number of research reports. Truist Financial reaffirmed a “buy” rating and set a $550.00 price target (up previously from $508.00) on shares of Vertex Pharmaceuticals in a research report on Monday, August 5th. Oppenheimer lifted their target price on Vertex Pharmaceuticals from $500.00 to $550.00 and gave the stock an “outperform” rating in a report on Monday, August 5th. Canaccord Genuity Group increased their price target on shares of Vertex Pharmaceuticals from $371.00 to $376.00 and gave the stock a “sell” rating in a report on Wednesday, July 31st. UBS Group increased their price objective on shares of Vertex Pharmaceuticals from $477.00 to $562.00 and gave the stock a “buy” rating in a research note on Thursday, October 17th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $600.00 price target on shares of Vertex Pharmaceuticals in a report on Monday. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat, Vertex Pharmaceuticals presently has an average rating of “Hold” and an average target price of $492.92.

Vertex Pharmaceuticals Price Performance

Shares of Vertex Pharmaceuticals stock traded down $3.62 during mid-day trading on Tuesday, reaching $474.47. 685,856 shares of the stock traded hands, compared to its average volume of 1,172,884. The company has a quick ratio of 2.26, a current ratio of 2.52 and a debt-to-equity ratio of 0.02. The business has a 50-day moving average of $475.48 and a 200 day moving average of $460.75. The stock has a market capitalization of $122.44 billion, a PE ratio of 30.82 and a beta of 0.40. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $341.90 and a fifty-two week high of $510.64.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Thursday, August 1st. The pharmaceutical company reported ($12.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($12.54) by ($0.29). The firm had revenue of $2.65 billion during the quarter, compared to analysts’ expectations of $2.66 billion. Vertex Pharmaceuticals had a negative net margin of 4.74% and a negative return on equity of 2.45%. The company’s revenue for the quarter was up 6.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.53 EPS. On average, analysts predict that Vertex Pharmaceuticals Incorporated will post -2.11 EPS for the current year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.